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In this issue of Neuron, Gime´nez-Cassina et al. (2012) show that fuel utilization by neuronal mitochondria,
controlled by the Bcl-2 family member BAD, defines response to seizures. Control of KATP channels by
mitochondrial metabolism might be a target for antiepileptic therapies.Proper neuronal electrical signaling is
crucial for coordinated activity of the
brain: when this is malfunctioning,
epileptic seizures, defined as a ‘‘transient
occurrence of signs and/or symptoms
due to abnormal excessive or synchro-
nous neuronal activity in the brain’’ (Fisher
et al., 2005), can arise. However, despite
this simple definition, pathogenesis of
seizures and of epilepsy is very complex.
The early oversimplification that seizures
result from a disruption of the equilibrium
between neuronal excitation and inhibi-
tion has been surpassed by a more inte-
grated view. If we oversimplify our current
understanding of how the brain functions,
we can say that it results from the in-
tegration of multiple cortical networks.
Inhibitory neurons, interneuronal synaptic
transmission and intrinsic neuronal prop-
erties control the continuous oscillation
of these networks. Seizures can result
from greater spread and neuronal recruit-
ment, caused by the combination of
enhanced connectivity and excitatory
transmission, reduced inhibitory mecha-
nisms, and changes in intrinsic neuronal
properties. Indeed, currently used anti-
convulsant drugs remodulate neuronal
activity, increasing inhibition, decreasing
excitation, or preventing aberrant burst-
firing of neurons; ultimately, these drugs
prevent excitotoxicity that may lead to
brain damage. However, anticonvulsants
are not always effective and a cohort
of patients is refractory to the current
pharmacological treatments. Alternative
options range from surgery to diet-
dependent glucose limitation (e.g., keto-
genic diet) that is recommended for the
treatment of pharmacoresistant cases of
juvenile epilepsy (Kossoff, 2004).
The efficacy of the dietary therapy in
children with epilepsy points to a role for600 Neuron 74, May 24, 2012 ª2012 Elseviermetabolism as a component of the patho-
genesis of seizures. Neuronal electrical
activity clearly depends on energy metab-
olism, and therefore on mitochondrial
respiration (MacAskill et al., 2010). It is
conceivable that administration of alter-
native metabolic substrates might influ-
ence neuronal excitability, although the
molecular mechanism of the dependence
of activity on metabolic substrates is not
fully understood.
Mitochondria are at the crossroad of
the most important catabolic pathways,
being able to use reducing equivalents
from glycolysis, fatty acid beta-oxidation
as well as catabolism of amino acids to
convert them into ATP. Multiple steps of
fine regulation are therefore operative to
allow efficient utilization of the different
substrates available to the cell. Mitochon-
dria are also crucial in the regulation of
diverse cellular responses that ranges
from apoptosis (Danial and Korsmeyer,
2004) to autophagy (Gomes et al., 2011).
These pathways are often intertwined
with the control of metabolism, as exem-
plified by the function of BAD (BCL-2
associated agonist of cell death), a proa-
poptotic member of the family of Bcl-2
death regulators, in glucose metabolism
and utilization (Danial et al., 2003, 2008).
Whether the regulation of neuronal ex-
citability depends on how mitochondria
shape intermediate metabolism is how-
ever unclear. With this question in mind,
Gime´nez-Cassina et al. (2012) investi-
gated the potential role of BAD in sei-
zures, unraveling in this issue of Neuron
the existence of a phosphodependent
regulatory switch in BAD that reduces
neuronal excitability upon kainic acid-
induced seizures.
BAD exists in a phosphorylated and de-
phosphorylated state, which have oppo-Inc.site effects on cell death. Dephos-
phorylated BAD goes to mitochondria,
where it interacts with prosurvival proteins
BCL-2 andmuchmore strongly with BCL-
XL, sensitizing mitochondria to the action
of other BH3-only proapoptotic proteins
that can initiate BAX/BAK-dependent
apoptosis (Yang et al., 1995). BAD can
be specifically phosphorylated on one
or multiple specific residues by different
protein kinases, including Rsk, PKC,
PKB, PKA, and phosphatidylinositol-3-
kinase (PI3K). BAD dephosphorylation
is also finely tuned by different phos-
phatases, including PP1, PP2A, and
Calcineurin (CnA, also known as PP2B)
(Klumpp and Krieglstein, 2002). Phos-
phorylation of different residues has dif-
ferent effects: for example, phosphory-
lation of Serine 155 impairs BAD
interaction with BCL2/BCL-XL, whereas
upon phosphorylation of Serine 112 and
Serine 136, binding sites are exposed for
its interaction with the cytosolic 14-3-3
proteins. In parallel to and separate from
its role in apoptosis, BAD also controls
glucose metabolism (Danial et al., 2003).
In this respect, BAD phosphorylation
does not only prevent initiation of cell
death, but it is also required for efficient
mitochondrial utilization of glucose in
liver, via the scaffolding of a complex con-
taining glucokinase on the surface of the
organelle (Danial et al., 2003).
Similarly to what occurs in liver,
Gime´nez-Cassina et al. (2012) show that
also cortical neurons and astrocytes from
Bad/mice display lower glucose utiliza-
tion for mitochondrial respiration. In-
triguingly, cortical neurons and astrocytes
from mice bearing a phosphodeficient
knockin allele of Bad at serine 155
(BadS155A) harbor the same defect. Con-
versely, mitochondrial consumption of
Figure 1. BAD Phosphorylation Controls Mitochondrial Fuel Utilization to Switch Neuronal
Excitability
The proapoptotic BH3-only protein BAD can be viewed as a relay: its phosphorylation on Ser 155 switches
the preferred source of reducing equivalents for mitochondria from glucose to ketones. Plasmamembrane
KATP channels are closed in neurons with ‘‘glycolytic’’ mitochondria, as opposed to the ones where
mitochondria use ketone bodies and that are less susceptible to seizures.
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hydroxybutyrate (a ketone body) is in-
creased. Therefore, mitochondria lacking
Bad selectively switch from glucose to
ketone body utilization, whereas BAD
phosphorylation on serine 155 favors the
opposite switch, from ketone body to
glucose. These results suggest an inter-
esting parallelism, at least in terms of fuels
used by mitochondria, between mice
where BAD is absent or not phosphoryl-
able, and animals on a ketogenic diet
that ameliorates seizures. The authors
therefore investigated whether BADmight
also influence seizure sensitivity in vivo.
Bad/ as well as BadS155A mice are
significantly protected from the procon-
vulsant drug kainic acid. Decreased sen-
sitivity to seizure response does not result
from an impairment of normal brain func-
tion in Bad/ and BadS155A mice that
displayed normal cognitive and motor
abilities. Moreover, seizure resistance is
specific for BAD and independent from
its proapoptotic function, pointing there-
fore to its role in metabolism.
Neuronal electrical excitability is linked
to the activity of ATP-sensitive K+ (KATP)
channels. KATP channels are activated
following decreased intracellular ATP, in
a negative feedback loop that is believed
to help neurons to overcome excitotoxic-
ity during seizure. High electrical activity
during seizure increases Na+ influx, which
prompts Na+-K+ ATPase to actively pump
Na+ outside the cells in a severely endoer-
gonic process. The subsequent decreasein ATP levels opens KATP channels,
tempering excitability during high-activity
states (Tanner et al., 2011). Ketogenic
diet increases the activity of KATP chan-
nels (Ma et al., 2007), explaining how
ketone bodies could ameliorate seizure
response. Inspired by this earlier work,
Gime´nez-Cassina et al. (2012) questioned
whether KATP channels played a role in the
resistance to seizures of Bad mutant
mice. Indeed they found that the open
probability of single KATP channels was
increased in dentate granule neurons
(DGNs) of hippocampal slices from
Bad/ mice. Whole-cell KATP currents in
DGNs were also increased in Bad/ or
BadS155A mice. In accordance with the
hypothesis that Bad mutant mice were
more resistant to seizure because of the
increased activity of KATP channels,
ablation of KATP channels expression in
Bad/ mice diminished their resistance
to seizures (Figure 1).
This important study provides insight
into a previously unknown signaling path-
way, linking BAD phosphorylation and
KATP channels activity to the attenua-
tion of seizures. Thanks to the elegant
combination of genetics, bioenergetics,
and electrophysiology, Gime´nez-Cassina
et al. (2012) unveil that fuel utilization by
neuronal mitochondria is not a ‘‘simple’’
question of thermodynamic efficiency
of the cell, but it crucially controls the
neuronal excitatory properties. Impor-
tantly, the phosphorylation status of a
moonlighting protein like BAD, with a dayNeuronjob inapoptosisandanight one in the scaf-
folding of glycolytic complexes on the
surface of mitochondria (Danial and Kors-
meyer, 2004), allows thismetabolic switch.
This finding paves the way to the design of
new drugs, which might be able to mimic
BAD activity and to stimulate a switch
among respiratory substrates in neuronal
mitochondria: for example, PKA that
phosphorylates Serine 155 of BAD
(Lizcano et al., 2000) could be an attractive
target to modulate seizure as well as
fuel utilization by mitochondria. Interest-
ingly, PKA inhibitors reduce efficiency of
mitochondrial ATP production in starved
cells by blocking autophagy-induced
mitochondrial elongation (Gomes et al.,
2011), opening the possibility that the
BADcomplex is also a hubwheremorpho-
logical and metabolic cues meet.
We are just beginning to unravel
the complex loop between mitochondrial
metabolism and seizures. For example,
although Gime´nez-Cassina et al. (2012)
convincingly show that the activity of
KATP channels is enhanced in Bad
/
and BadS155A mice, the molecular link
between BAD and opening time of KATP
channels is still obscure. In cardiac cells,
the intracellular pool of KATP channels is
mobile and can relocate to the sarco-
lemma after ischemia, increasing their
surface density (Bao et al., 2011). Simi-
larly, it is conceivable that in Bad/ and
BadS155A neurons, the density of KATP
channels on the plasma membrane might
be enhanced, following a yet unknown
mechanism of BAD-dependent regulation
of endocytic recycling. Alternatively, the
KATP channels might be activated by a
signal emanating from mitochondria only
when they preferentially use fatty acids:
a similar ‘‘second messenger’’ has been
identified in glutamate, released from
beta-cells mitochondria upon glucose
stimulation to promote insulin secretion
(Maechler and Wollheim, 1999).
In conclusion, the work of Gime´nez-
Cassina et al. (2012) paves the way
toward the understanding of the molec-
ular mechanisms of mitochondrial and
metabolic control of seizures.REFERENCES
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